Core Insights - STRATA Skin Sciences, Inc. has received confirmation from the Centers for Medicare & Medicaid Services (CMS) regarding continued reimbursement for excimer laser treatments, with an expansion of CPT code descriptors expected in 2027 [1][2][7] Group 1: Reimbursement and Regulatory Updates - CMS has affirmed ongoing reimbursement for excimer laser treatments under CPT codes 96920, 96921, and 96922, ensuring uninterrupted patient access [7] - The Final Rule indicates a payment increase of approximately 3.5% for all three codes in calendar year 2026 compared to 2025 [7] - The current CPT code family remains exclusive to excimer laser technology until at least the 2027 descriptor updates, reinforcing STRATA's position against other technologies being billed under these codes [7] Group 2: Future Indications and Clinical Engagement - CMS recognizes the upcoming expansion of excimer laser procedure eligibility to include additional inflammatory and autoimmune conditions, effective January 1, 2027 [7] - STRATA is actively engaging with commercial insurance providers to ensure that individual coverage policies extend the excimer laser exclusivity beyond 2027 [3][4] - The company plans to incorporate extensive clinical and real-world cost data in the 2027 rulemaking process, which will be reviewed alongside recommendations from the American Medical Association (AMA) [2][4] Group 3: Commitment to Patients and Providers - STRATA's XTRAC excimer laser is FDA-cleared and clinically proven for treating various dermatologic conditions, including psoriasis and vitiligo [6] - The company is committed to partnering with clinicians, patient advocates, and payers to ensure the availability of safe and effective treatment options [6] - STRATA supports over 840 partner clinics and aims to expand the adoption of excimer laser procedures across immune-mediated skin diseases [4]

Core Insights - STRATA Skin Sciences is working with CMS to obtain temporary codes for expanded reimbursement of its XTRAC excimer laser treatment, aiming for implementation as early as the 2026 rule cycle [2][3] - The American Medical Association has approved updates to CPT codes, expanding reimbursement eligibility for XTRAC treatments to include various inflammatory and autoimmune skin conditions effective January 1, 2027 [2] - STRATA's efforts could potentially triple the addressable patient population, benefiting over 30 million individuals with chronic skin conditions [3] Company Developments - STRATA has received significant support from legislators, patient advocacy groups, and academic leaders, reinforcing confidence in the efficacy of Excimer Laser therapy [4] - Recent peer-reviewed studies have confirmed the safety and effectiveness of combining 308-nm excimer laser therapy with JAK inhibitors for treating vitiligo, with one study showing a 100% overall response rate [5][6] - The company is involved in ongoing litigation against LaserOptek America, with the Federal District Court agreeing to add LaserOptek Korea as a defendant, indicating potential for significant damages [7][8] Product and Market Strategy - STRATA's XTRAC excimer laser is positioned as a leading drug-free option for treating skin conditions, with a focus on enhancing patient outcomes [4][9] - The company offers a unique Partnership Program that includes a fee per treatment cost structure, on-site training, and marketing support to promote its technologies [11] - STRATA's intellectual property portfolio includes patents for localized treatment methods, positioning the company for future growth in the dermatology market [9]